Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial

BACKGROUND: Chronic kidney disease is associated with increased arterial stiffness even in the early stages and this is thought to be a key mediator in the pathophysiology of the increased cardiovascular risk associated with this condition. The use of low-dose spironolactone has previously been show...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Khai P, Jain, Poorva, Heer, Gurdip, Redman, Val, Chagoury, Odette L, Dowswell, George, Greenfield, Sheila, Freemantle, Nick, Townend, Jonathan N, Gill, Paramjit S, McManus, Richard J, Ferro, Charles J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113230/
https://www.ncbi.nlm.nih.gov/pubmed/24886272
http://dx.doi.org/10.1186/1745-6215-15-158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113230/
https://www.ncbi.nlm.nih.gov/pubmed/24886272
http://dx.doi.org/10.1186/1745-6215-15-158

Ejemplares similares